Immuneotherapy Flashcards

1
Q

first immunotherapy drug

A

Coley’s Toxin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what would happen if we used a mouse antibody in human

A

body will clear it via the immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what do B cells produce

A

antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

-omab

A

mouse antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

-iximab

A

chimeric antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

-zumab

A

humanized

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

-umab

A

fully human

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

explain the two tiered effect of antibodies

A

binding of antibodies to receptor on surface of cancer cells can lead to CDC or ADCC complement or antibody dependent cytotoxicity
inhibit receptor and kill cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is trastuzumab class

A

humanized mab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

trastuzumab target

A

HER2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

trastuzumab increased risk of cardiomyopathy with what drug

A

adriamycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

how does trastuzumab work?

A

antibody dependent cytotoxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

pertuzumab used in combo with what

A

trastuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

pertuzumab does what

A

binds HER2 receptor and prevents dimerization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what drugs were in CLEOPATRA trial?

A

trastuzumab
pertuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

cetuximab binds what

A

EGFR extracellular domain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what does cetuximab do (3)

A

blocks phosphorylation of kinases
inhibits cell growth and induces apoptosis
comp inhibits binding of EGF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

cetuximab indications

A

colorectal cancer
head / neck cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

cetuximab side effects

A

rash

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

EGFR inhibitors have what side effect?

A

rash, means better prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what is panitumumab

A

like cetuximab but without the infusion toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

bevacizumab target

A

VEGF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

bevacizumab does what

A

binds VEGF ligand and blocks int with endothelial receptors
blocks endothelial cell prolif and new blood vessel form
inhibits solid tumor growth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

bevacizumab used with what

A

5-FU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

what binds VEGF ligand

A

bevicizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

what binds VEGF receptor

A

ramucirumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

what works with B cells receptor to drive proliferation of B cells

A

CD20

28
Q

what is CD20 expressed by?

A

normal B lymphocytes
immature pre-B cells

29
Q

what disease state is CD20 expressed on B cells

A

non-Hodgkins lymphoma

30
Q

what is rituximab target

A

CD20

31
Q

what is rituximab for

A

B cell lymphoma (non-Hodgkins lymphoma)

32
Q

what does daratumumab target

A

CD38

33
Q

what does daratumumab treat

A

multiple myeloma

34
Q

CD38 expressed on what cells

A

plasma cells
(multiple myeloma)

35
Q

what drugs are in T-DM1

A

emtansine and trastuzumab

36
Q

what is emtansine

A

cytotoxic microtubule assembly inhibitor

37
Q

T-DM1use

A

HER2 + breast cancer, second line

38
Q

how is the purpose of using T-DM1 combo

A

reduced toxicity side effects

39
Q

CD3 is on what type of cells

A

T cells

40
Q

side effect from immunotherapies

A

cytokine storm, massive infection

41
Q

blinatumomab targets and treats what

A

CD3 t cell
CD19 B cell
ALL

42
Q

mosunetuzumab target and treats what

A

CD3 T cell
CD20 B cell
non hodgkin lymphoma

43
Q

teclistamab target and treats

A

CD3
BCMA
multiple myeloma

44
Q

taquetamab target and treats

A

CD3
GPRC5D
multiple myeloma

45
Q

Bite drugs

A

blinatumomab
mosunetuzumab
teclistamab
taquetamab

46
Q

ALL antigen

A

CD19

47
Q

MM antigens

A

BCMA
CD38
GPRC5D

48
Q

non hodgkin lymphoma antigens

A

CD20

49
Q

ipilmumab target

A

CTLA-4 receptor

50
Q

ipilumumab treats what

A

metastatic melanoma

51
Q

ipilumab side effectg

A

sever immune response

52
Q

what drug targets CTLA-4

A

ipilumumab

53
Q

what drug targets PD-1

A

pembrolizumab
(Keytruda)

54
Q

what does pembrolizumab target

A

PD-1

55
Q

PD-1 is where

A

T cells

56
Q

PDL-1 is where

A

macrophages and tumor cells

57
Q

pembrolizumab indications

A

advanced metastatic melanoma following ipilumab and a BRAF inhibitor
NSCLC if PDL-1 positive

58
Q

pembrolizumab can be used in NSCLC if what

A

PD-L1 positive

59
Q

pembrolizumab can be used in metastatic melanoma if what

A

tried treatment with Ipilmumab and if BRAFV600 mutation a BRAF inhibitor

60
Q

which drug targets PD-L1

A

atezolizumab

61
Q

what does atelizumab target

A

PD-L1

62
Q

what is cell therapy

A

take antigen presenting cells out of pt
activate with drug ex vivo
put back in pt
want to stimulate pts own immune system to attack the cancer

63
Q

what is the cell therapy drug

A

sipulcel T

64
Q

what is sipulcel-T indicated for

A

minimally symptomatic metastatic hormome refractory prostate cancer

65
Q

what is the common target of CART therapy

A

CD19